{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:16:58Z","timestamp":1791911818190,"version":"4.3.4"},"reference-count":47,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Spinal radiographic progression is an important outcome in radiographic axial spondyloarthritis (SpA). The objective of the phase IIIb SURPASS study was to\u00a0compare spinal radiographic progression in patients with radiographic axial SpA treated with secukinumab (interleukin\u201017A inhibitor) versus adalimumab biosimilar (Sandoz adalimumab [SDZ\u2010ADL]; tumor necrosis factor inhibitor).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Biologic\u2010naive patients with active radiographic axial SpA, at high risk of radiographic progression (high\u2010sensitivity C\u2010reactive protein [hsCRP] \u22655 mg\/L and\/or \u22651 syndesmophyte[s] on spinal radiographs), were randomized (1:1:1) to secukinumab (150\/300 mg) or SDZ\u2010ADL (40 mg). The proportion of patients with no radiographic progression (change from baseline [CFB] in modified Stoke Ankylosing Spondylitis Spinal Score [mSASSS] \u22640.5) on secukinumab versus SDZ\u2010ADL at week 104 (primary endpoint), mean CFB\u2010mSASSS, proportion of patients with \u22651 syndesmophyte(s) at baseline with no new syndesmophyte(s), and safety were evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 859 patients (78.5% male, mSASSS 16.6, Bath Ankylosing Spondylitis Disease Activity Index 7.1, hsCRP 20.4 mg\/L, and 73.0% with \u22651 syndesmophyte[s]) received secukinumab 150 mg (n = 287), secukinumab 300 mg (n = 286), or SDZ\u2010ADL (n = 286). At week 104, the proportion of patients with no radiographic progression was 66.1%, 66.9%, and 65.6% (<jats:italic>P<\/jats:italic> = not significant, both secukinumab doses) and mean CFB\u2010mSASSS was 0.54, 0.55, and 0.72 in secukinumab 150 mg, secukinumab 300 mg, and SDZ\u2010ADL arms, respectively. Overall, 56.9%, 53.8%, and 53.3% of patients on secukinumab 150 mg, secukinumab 300 mg, and SDZ\u2010ADL, respectively, with \u22651 syndesmophyte(s) at baseline did not develop new syndesmophyte(s) by week 104. There were no unexpected safety findings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Spinal radiographic progression over two years was low with no significant difference between secukinumab and SDZ\u2010ADL arms. The safety of both treatments was consistent with previous reports.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.42852","type":"journal-article","created":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T02:33:44Z","timestamp":1711938824000},"page":"1278-1287","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Effect of Secukinumab Versus Adalimumab Biosimilar on Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: Results From a <scp>Head\u2010to\u2010Head<\/scp> Randomized Phase <scp>IIIb<\/scp> Study"],"prefix":"10.1002","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-9362","authenticated-orcid":false,"given":"Xenofon","family":"Baraliakos","sequence":"first","affiliation":[{"name":"Ruhr\u2010University  Herne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel","family":"\u00d8stergaard","sequence":"additional","affiliation":[{"name":"Rigshospitalet, Glostrup, Denmark, and University of Copenhagen  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4537-6015","authenticated-orcid":false,"given":"Denis","family":"Poddubnyy","sequence":"additional","affiliation":[{"name":"Charit\u00e9 Universit\u00e4tsmedizin Berlin and German Rheumatism Research Centre  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center  Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2130-1246","authenticated-orcid":false,"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[{"name":"Oregon Health &amp; Science University  Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8411-7972","authenticated-orcid":false,"given":"Pedro M.","family":"Machado","sequence":"additional","affiliation":[{"name":"University College London  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Navarro\u2010Comp\u00e1n","sequence":"additional","affiliation":[{"name":"La Paz University Hospital  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6142-3814","authenticated-orcid":false,"given":"Kay Geert A.","family":"Hermann","sequence":"additional","affiliation":[{"name":"Charit\u00e9 Universit\u00e4tsmedizin Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4007-1589","authenticated-orcid":false,"given":"Mitsumasa","family":"Kishimoto","sequence":"additional","affiliation":[{"name":"Kyorin University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6975-8627","authenticated-orcid":false,"given":"Eun Young","family":"Lee","sequence":"additional","affiliation":[{"name":"Seoul National University College of Medicine  Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6314-5336","authenticated-orcid":false,"given":"Lianne S.","family":"Gensler","sequence":"additional","affiliation":[{"name":"University of California San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5668-4497","authenticated-orcid":false,"given":"Uta","family":"Kiltz","sequence":"additional","affiliation":[{"name":"Ruhr\u2010University  Herne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco F.","family":"Eigenmann","sequence":"additional","affiliation":[{"name":"Novartis Pharma  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Pertel","sequence":"additional","affiliation":[{"name":"Novartis Pharma  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Readie","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals  East Hanover New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanno B.","family":"Richards","sequence":"additional","affiliation":[{"name":"Novartis Pharma  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Porter","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals  East Hanover New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Braun","sequence":"additional","affiliation":[{"name":"Rheuma Praxis Berlin, Berlin, Germany, and Ruhr\u2010Universit\u00e4t Bochum  Bochum Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,4,30]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31591-4"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215707"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.02.007"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00194-8"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.33465"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204055"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205178"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209209"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41042"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223296"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001654"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1490-y"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001099"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001005"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key375"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177231"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23097"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001170"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216741"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2018.1506822"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211544"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38070"},{"key":"e_1_2_8_27_1","volume-title":"Hyrimoz assessment report","year":"2018"},{"key":"e_1_2_8_28_1","volume-title":"Hyrimoz summary of product characteristics","year":"2022"},{"key":"e_1_2_8_29_1","volume-title":"Hyrimoz prescribing information","year":"2022"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-020-00886-7"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/75.4.800"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3495"},{"key":"e_1_2_8_33_1","volume-title":"Addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials E9(R1)","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)","year":"2019"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.018457"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202939"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.066415"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.145995"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e328352b7bd"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203148"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2019.19073"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key128"},{"issue":"10","key":"e_1_2_8_42_1","first-page":"2048","article-title":"Selection of a method for scoring radiographs for ankylosing spondylitis clinical trials, by the Assessment in Ankylosing Spondylitis Working Group and OMERACT","volume":"32","author":"Van der Heijde D","year":"2005","journal-title":"J Rheumatol"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222747"},{"issue":"4","key":"e_1_2_8_44_1","first-page":"862","article-title":"Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment","volume":"34","author":"Lukas C","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209730"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20906040"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222324"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez363"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.42852","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T14:07:28Z","timestamp":1759932448000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.42852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,30]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1002\/art.42852"],"URL":"https:\/\/doi.org\/10.1002\/art.42852","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,30]]},"assertion":[{"value":"2023-12-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}